Abstract
One strategy for the use of neural stem cells (NSCs) in treating neurological disorders is as transplantable “biological minipumps”, in which genetically engineered neural stem cells serve as sources of secreted therapeutic (neuroprotective or tumoricidal) agents. Neural stem cells are highly mobile within the brain and demonstrate a tropism for various types of central nervous system (CNS) pathology, making them promising candidates for targeted gene delivery vehicles. Although neural stem cells have also been proposed as a potential source of replacement neurons and astrocytes to repopulate injured or degenerating neural circuits, the challenges involved in rebuilding damaged brain architecture are substantial and remain an active area of investigation. In contrast, the use of NSCs as biological minpumps does not rely on neuronal differentiation, axonal targeting, or synaptogenesis. This strategy may be a faster route to cell-based therapy of the CNS and is poised to move into human clinical trials. This review considers two types of neurologic disease that may be suitable targets for this alternative approach to NSC therapy: glial brain tumors and traumatic brain injury. We examine some of the key scientific and technical issues that must be addressed for the successful use of NSCs as minipumps.
Keywords: Neural progenitor/stem cell, CNS transplantation, trophic factors, traumatic brain injury, glioblastoma
Current Stem Cell Research & Therapy
Title: Neural Stem Cells as Biological Minipumps: A Faster Route to Cell Therapy for the CNS?
Volume: 2 Issue: 1
Author(s): H. Isaac Chen, Asha Bakshi, Nicolas C. Royo, Suresh N. Magge, Deborah J. Watson, Nicolas C. Royo, Suresh N. Magge and Deborah J. Watson
Affiliation:
Keywords: Neural progenitor/stem cell, CNS transplantation, trophic factors, traumatic brain injury, glioblastoma
Abstract: One strategy for the use of neural stem cells (NSCs) in treating neurological disorders is as transplantable “biological minipumps”, in which genetically engineered neural stem cells serve as sources of secreted therapeutic (neuroprotective or tumoricidal) agents. Neural stem cells are highly mobile within the brain and demonstrate a tropism for various types of central nervous system (CNS) pathology, making them promising candidates for targeted gene delivery vehicles. Although neural stem cells have also been proposed as a potential source of replacement neurons and astrocytes to repopulate injured or degenerating neural circuits, the challenges involved in rebuilding damaged brain architecture are substantial and remain an active area of investigation. In contrast, the use of NSCs as biological minpumps does not rely on neuronal differentiation, axonal targeting, or synaptogenesis. This strategy may be a faster route to cell-based therapy of the CNS and is poised to move into human clinical trials. This review considers two types of neurologic disease that may be suitable targets for this alternative approach to NSC therapy: glial brain tumors and traumatic brain injury. We examine some of the key scientific and technical issues that must be addressed for the successful use of NSCs as minipumps.
Export Options
About this article
Cite this article as:
Isaac Chen H., Bakshi Asha, Royo C. Nicolas, Magge N. Suresh, Watson J. Deborah, C. Royo Nicolas, N. Magge Suresh and J. Watson Deborah, Neural Stem Cells as Biological Minipumps: A Faster Route to Cell Therapy for the CNS?, Current Stem Cell Research & Therapy 2007; 2 (1) . https://dx.doi.org/10.2174/157488807779317044
DOI https://dx.doi.org/10.2174/157488807779317044 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Brain Innate Immunity in the Regulation of Neuroinflammation: Therapeutic Strategies by Modulating CD200-CD200R Interaction Involve the Cannabinoid System
Current Pharmaceutical Design Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review of SIRTUIN Activators as Potential Immunomodulators and their Influences on other Dysfunctions
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Inflammatory Biomarkers in Cardiovascular Therapeutics
Current Medicinal Chemistry Mitochondria Sentencing About Cellular Life and Death: A Matter of Oxidative Stress
Current Pharmaceutical Design Endogenous Regulation of Neural Stem Cells in the Adult Mammalian Brain
Central Nervous System Agents in Medicinal Chemistry A Mini Review on Interactions Between Neural Stem Cells and Biomaterials
Recent Patents on Regenerative Medicine Glucocorticoids Pharmacology: Past, Present and Future
Current Pharmaceutical Design An Outline of the Historical and Clinical Aspects of Catatonic Schizophrenia
Current Psychiatry Reviews Effects of Erythropoietin on Brain Function
Current Pharmaceutical Biotechnology Adenosine Deaminase in the Modulation of Immune System and its Potential as a Novel Target for Treatment of Inflammatory Disorders
Current Drug Targets Increasing Expression of Heme Oxygenase-1 by Proteasome Inhibition Protects Astrocytes from Heme-mediated Oxidative Injury
Current Neurovascular Research Regulatory Cross Talks of Bone Cells, Hematopoietic Stem Cells and the Nervous System Maintain Hematopoiesis
Inflammation & Allergy - Drug Targets (Discontinued) Genetic Variations in CHRNA7 or CHRFAM7 and Susceptibility to Dementia
Current Drug Targets The Role of Negative Costimulators During Parasitic Infections
Endocrine, Metabolic & Immune Disorders - Drug Targets Synthesis of Medicinally Privileged Heterocycles through Dielectric Heating
Current Medicinal Chemistry The Ubiquitin-Proteasome System and Proteasome Inhibitors in Central Nervous System Diseases
Cardiovascular & Hematological Disorders-Drug Targets Nanoemulsions for Skin Targeting: Present Status and Future Prospects
Drug Delivery Letters Artificial Intelligence, Big Data and Machine Learning Approaches in Precision Medicine & Drug Discovery
Current Drug Targets A Magnetic Resonance Spectroscopy Study of Lovastatin for Treating Bipolar Mood Disorder: A 4-Week Randomized Double-Blind, Placebo- Controlled Clinical Trial
Recent Patents on Inflammation & Allergy Drug Discovery Inhibition of microRNA-155 Alleviates Neurological Dysfunction Following Transient Global Ischemia and Contribution of Neuroinflammation and Oxidative Stress in the Hippocampus
Current Pharmaceutical Design